Veterinary Medicines

Apovomin 1 mg/ml solution for injection for dogs

Authorised
  • Apomorphine hydrochloride hemihydrate
Download as PDF

Product identification

Medicine name:
Apovomin 1 mg/ml solution for injection for dogs
Apovomin 1 mg/ml, injekcinis tirpalas šunims
Active substance:
  • Apomorphine hydrochloride hemihydrate
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Apomorphine hydrochloride hemihydrate
    1.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN04BC07
Legal status of supply:
This information is not available for this product.
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Package description:
  • Clear Type I glass vials containing 5 ml, closed with a coated Type I bromobutyl rubber stopper and sealed with an aluminium cap. Each vial is packed into a cardboard box.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Dechra Regulatory B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Produlab Pharma B.V.
Responsible authority:
  • SFVS
Authorisation number:
  • LT/2/20/2634/001
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0343/001
Concerned member states:
  • Austria
  • Bulgaria
  • Croatia
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

RV2634.pdf

Lithuanian (PDF)
Published on: 30/05/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."